Malaria Clinical Trials Center General Screening (GS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02119312|
Recruitment Status : Suspended (COVID19 safety measures-institutional policy to suspend non-covid related studies)
First Posted : April 21, 2014
Last Update Posted : June 16, 2020
|Condition or disease|
This is a continuous study enrolling approximately 350 participants per year to establish preliminary eligibility for participation in ongoing or future Seattle Malaria Clinical Trials Center (Seattle MCTC) clinical research studies. Data collected may be used to support preliminary eligibility for a current or future Seattle MCTC clinical research study.
In order to maximize efficiency of the screening process potential participants who contact the site will be pre-screened using an IRB-approved screening form.
Potential participants who contact the site may be asked to come in for an in-person screening visit. They will be given a consent form to read and sign if they should choose to participate in the screening process. If they have any questions during this process research staff will be available. This visit includes an in-depth medical history review, travel history, physical exam, blood draw, electrocardiogram test (ECG), and a urine test.
The Seattle Malaria Clinical Trials Center (Seattle MCTC) is conducting research to combat malaria. Malaria is a disease that is transmitted to humans by the bite of an infected mosquito and affects millions of people worldwide. Malaria can cause a wide range of medical problems, and may even result in death if the infection is not treated. Currently there are many medications, preventative measures and malaria vaccines being developed to fight malaria that will need to be tested before they can be made available to the general public. The Seattle MCTC is conducting clinical research studies for this purpose and is in need of healthy adult volunteers to take part in upcoming studies.
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||3500 participants|
|Target Follow-Up Duration:||1 Year|
|Official Title:||General Screening for Eligibility to Participate in Treatment, Prevention and Vaccine Trials at the Seattle Malaria Clinical Trials Center|
|Study Start Date :||June 2010|
|Estimated Primary Completion Date :||September 1, 2020|
|Estimated Study Completion Date :||September 14, 2020|
- Participant Enrollment [ Time Frame: Once upon enrollment ]See inclusion/exclusion criteria.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02119312
|United States, Washington|
|Fred Hutchinson Cancer Research Center|
|Seattle, Washington, United States, 98109|
|Principal Investigator:||James G Kublin, MD||Fred Hutchinson Cancer Research Center|